The Brain on Meth: New Research Maps How Craving Hijacks Attention Before You Know It’s Happening

Consider the difference between these two experiences: waking up at 3 a.m. with a persistent, dull pull toward using — a background discomfort that just is — and walking past a neighborhood corner where you used to score and feeling something sharp, immediate, and overpowering kick in. Same person, same drug, same brain. Different mechanism.

A 2026 study in PMC examining craving trajectories across pharmacotherapy trials for methamphetamine use disorder formalizes what clinicians have observed for years: these are two distinct phenomena. Withdrawal craving is a persistent background state during abstinence — the result of dopaminergic depletion and neuroadaptation that persists long after the drug is cleared. Cue-induced craving is an acute, impulsive response triggered by drug-associated stimuli. They respond differently to different interventions, and conflating them produces treatment plans that address one while ignoring the other.

The second study — on attentional bias in methamphetamine use disorder — goes a level deeper. Attentional bias is a pre-conscious process: the visual attention system has been trained, through repeated drug-use pairings, to orient automatically toward drug-related cues before any conscious awareness registers. Research participants show measurable eye-movement biases toward drug-related images before they can report noticing them. This matters clinically because it means cue-induced craving isn’t something a person can “decide” their way around. The brain’s attention system is already acting on the environment. Conscious willpower arrives late.

The practical implication from these papers is pointed: contingency management and cognitive behavioral approaches are better suited to withdrawal craving (changing the behavioral environment, building new routines, addressing the chronic background state). Cue exposure therapy — deliberately and systematically exposing people to drug-related stimuli in a controlled setting until the cue-response extinguishes — is the more direct approach to attentional bias and cue-induced craving. Both have evidence bases. Neither is adequately reimbursed or widely deployed in US treatment settings.

On the pharmacotherapy side, the ADAPT-2 data on naltrexone-bupropion — the only pharmacological treatment with meaningful evidence for methamphetamine use disorder — shows reduced cue-induced craving versus placebo, consistent with the hypothesis that the opioid antagonism component of naltrexone blunts one of the reward pathways that amplifies cue reactivity.

None of this is a solved problem. But knowing that craving has architecture — that it is not a single undifferentiated urge but a set of distinct mechanisms with potentially distinct interventions — is the kind of scientific progress that turns “just don’t use” into something practitioners can actually work with.